►New Zealand Prime Minister Jacinda Ardern announced Friday the city of Auckland would join the rest of the country in having no restrictions other than an ongoing requirement to wear masks on public transport and planes.
Another COVID-19 candidate vaccine appears to be 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain in a United Kingdom trial.
On Thursday, Novavax, a Gaithersburg, Maryland-based biotechnology firm, reported in a final analysis of more than 15,000 patients in the U.K. that the overall vaccine efficacy was 89.7%, lowered slightly because of the B.1.1.7. strain first discovered in the country. The company also released results from the smaller South African trial, which exposed participants to the variant discovered and circulating there, that showed roughly 55.4% efficacy among 2,665 participants.
Send an email
